Yugal Sikri, chairman of the Pharmaceutical Management Program of the prestigious NMIMS University, and with an extremely rich experience in the pharmaceutical industry, explains his mission to build a valuable discussion platform for CEOs and institutions of the industry alike. Such industry efforts will ensure the Indian pharmaceutical industry efficiently addresses its issues, while continuing to be the pharmacy of the world and climb up the value chain.
You have over 35 years of experience in the pharma industry at senior leadership roles, including CEO at Ranbaxy, in both MNCs and local pharma companies. What has been driving you to take such roles and why have you decided to switch to the public sector as a professor at NMIMS?
"The investment trend is actually quite positive, with large Indian companies now understanding the importance of R&D. Today, the top five Indian companies invest around nine percent of their Sales turnover in R&D, compared to only five percent or even less a decade ago."
